Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Prostate Cancer (mCRPC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT06305598
What this trial is testing

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Roswell Park Cancer Institute 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT03230734
What this trial is testing

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 70
Testing effectiveness (Phase 2)Ended earlyNCT03207867
What this trial is testing

NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Who this might be right for
NSCLC, Non Small Cell Lung CancerRCC, Renal Cell CancerPancreatic Cancer+7 more
Novartis Pharmaceuticals 315
Not applicableLooking for participantsNCT07096999
What this trial is testing

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Who this might be right for
Metastatic Castration-Resistant Prostate Carcinoma
University of Michigan Rogel Cancer Center 60
Large-scale testing (Phase 3)Active Not RecruitingNCT03732820
What this trial is testing

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 895
Early research (Phase 1)Looking for participantsNCT07533708
What this trial is testing

A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours

Who this might be right for
mCRPC or Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech 48
Post-approval studies (Phase 4)Active Not RecruitingNCT05457257
What this trial is testing

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 43
Large-scale testing (Phase 3)Ended earlyNCT03850795
What this trial is testing

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer MetastaticCastration-resistant Prostate Cancer
Hinova Pharmaceuticals USA, Inc. 104
Early research (Phase 1)Ended earlyNCT04615845
What this trial is testing

Autologous Dendritic Cell Immunotherapy in Patients With mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Pharmicell Co., Ltd. 3
Testing effectiveness (Phase 2)Study completedNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Early research (Phase 1)Active Not RecruitingNCT07214961
What this trial is testing

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer (CRPC)Metastatic Castrate Resistant Prostate Cancer (mCRPC)
ARTBIO Inc. 80
Early research (Phase 1)Study completedNCT04397276
What this trial is testing

JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Who this might be right for
Neoplasms
Janssen Research & Development, LLC 82
Early research (Phase 1)WithdrawnNCT02380313
What this trial is testing

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

Who this might be right for
Cancer
GlaxoSmithKline
Early research (Phase 1)Not Yet RecruitingNCT07090369
What this trial is testing

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Peter MacCallum Cancer Centre, Australia 20
Testing effectiveness (Phase 2)Looking for participantsNCT07414940
What this trial is testing

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

Who this might be right for
Metastatic Castration-resistant Prostate CancerMetastatic Prostate CancerProstate Cancer
University College, London 60
Testing effectiveness (Phase 2)UnknownNCT02525068
What this trial is testing

Enzalutamide in Combination With AZD5363 in Patients With mCRPC

Who this might be right for
Adenocarcinoma of the Prostate
Institute of Cancer Research, United Kingdom 136
Testing effectiveness (Phase 2)Looking for participantsNCT07354594
What this trial is testing

External Beam and Radioligand Radiotherapy for mCRPC

Who this might be right for
Prostate Cancer Metastatic Castration-Resistant
Centre hospitalier de l'Université de Montréal (CHUM) 120
Large-scale testing (Phase 3)UnknownNCT04139772
What this trial is testing

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Who this might be right for
Metastatic Castration-resistent Prostate Cancer
National Cancer Institute, Naples 18
Not applicableTemporarily Not AvailableNCT06033001
What this trial is testing

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Castration-Resistant Prostatic Cancer
Lantheus Medical Imaging
Large-scale testing (Phase 3)Active Not RecruitingNCT02257736
What this trial is testing

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Neoplasms
Aragon Pharmaceuticals, Inc. 982
Next Page